Free delivery over $3201–3 day express deliveryDispatched Australia-wideIndependent lab reports published
Free bac water with any 2 vials · no code · ends Thu 26 NovBlack Fridayopens Fri 27 Nov ·  
Shop now

Eloralintide – 10mg

$220.00

Free Delivery on all orders above $320

Out of stock

Description

Eloralintide 10mg – LY3841136 Amylin Receptor Research Peptide Australia

Eloralintide 10mg, also identified by the development code LY3841136, is an investigational amylin-receptor agonist listed by Peps Aussie Australia as reference material for scientific investigation, laboratory analysis and controlled experimental research.

Eloralintide has attracted scientific interest because of its reported long-acting pharmacological characteristics and preferential activity at the AMY1 receptor in laboratory assays.

Amylin is a peptide hormone involved in metabolic signalling and the regulation of physiological processes associated with food intake and nutrient handling.

Amylin receptors belong to a family of receptor complexes formed through interactions between the calcitonin receptor and receptor activity-modifying proteins.

Experimental research involving Eloralintide has examined receptor pharmacology, signalling selectivity, pharmacokinetic characteristics and metabolic endpoints.

Early clinical development has also investigated tolerability and selected metabolic outcomes using specifically manufactured investigational drug material.

However, Eloralintide remains an investigational compound, and clinical trial results do not establish the identity, composition, safety or efficacy of material supplied by an unrelated source.

The characteristics of any research preparation must be independently established through appropriate product-specific analytical documentation.

Peps Aussie lists Eloralintide in a nominal 10mg size for laboratory research and analytical applications.

Important: Eloralintide is intended strictly for laboratory research and analytical purposes. It is not supplied for human or animal consumption, injection, administration, weight management, therapeutic use or clinical treatment.

What Is Eloralintide?

Eloralintide (LY3841136) is an investigational long-acting amylin-receptor agonist.

It has been studied for its interactions with amylin receptor complexes, particularly the AMY1 receptor.

Amylin receptors are formed through interactions between the calcitonin receptor and receptor activity-modifying proteins, commonly abbreviated as RAMPs.

The three principal amylin receptor subtypes are:

  • AMY1: Calcitonin receptor associated with RAMP1.
  • AMY2: Calcitonin receptor associated with RAMP2.
  • AMY3: Calcitonin receptor associated with RAMP3.

These receptor complexes can differ in their pharmacological responses to peptide ligands.

Eloralintide has demonstrated preferential activity at AMY1 in reported experimental assays.

However, receptor selectivity depends on the assay system, receptor expression and experimental conditions.

Understanding Amylin Receptor Research

Amylin is a peptide hormone co-secreted with insulin by pancreatic beta cells.

It participates in physiological signalling associated with nutrient intake and metabolic regulation.

Research involving amylin and related receptor agonists has examined:

  • Amylin receptor pharmacology.
  • Receptor activation.
  • Cellular signalling.
  • Food-intake-associated pathways.
  • Gastric physiology.
  • Metabolic regulation.
  • Peptide pharmacokinetics.
  • Receptor subtype selectivity.

These areas provide the scientific context for Eloralintide research.

Eloralintide Research and Scientific Applications

Published research involving Eloralintide and related amylin-receptor agonists spans several areas of receptor pharmacology, metabolic biology and investigational drug development.

The following sections describe scientific research topics rather than proven therapeutic effects of the Peps Aussie material.

1. AMY1 Receptor Pharmacology Research

One of the principal areas associated with Eloralintide research involves its reported preferential activity at the AMY1 receptor.

AMY1 is a receptor complex formed by the calcitonin receptor and RAMP1.

Experimental investigations have examined how amylin-related ligands interact with different receptor subtypes.

Relevant research topics include:

  • AMY1 receptor activation.
  • Ligand–receptor interactions.
  • Receptor subtype selectivity.
  • Concentration–response relationships.
  • Receptor-associated signalling.
  • Comparative pharmacology.
  • Experimental assay development.

These investigations contribute to understanding the pharmacological characteristics of amylin-receptor agonists.

2. Amylin Receptor Signalling Research

Amylin receptors belong to a broader family of G protein-coupled receptor complexes.

Their activation can influence intracellular signalling pathways.

Research involving amylin-receptor agonists has examined:

  • Receptor-mediated signalling.
  • Cyclic AMP-associated pathways.
  • G protein-coupled receptor biology.
  • Cellular response mechanisms.
  • Receptor expression.
  • Ligand-dependent signalling.
  • Pharmacological assay interpretation.

These investigations contribute to understanding the molecular behaviour of amylin-related compounds.

However, receptor activation observed in laboratory assays does not independently establish clinical efficacy.

3. Metabolic Signalling Research

Amylin participates in physiological processes associated with nutrient handling and metabolic regulation.

Experimental investigations involving amylin-receptor agonists have examined how receptor activation relates to metabolic signalling.

Relevant research topics include:

  • Metabolic regulatory pathways.
  • Nutrient-associated signalling.
  • Receptor-mediated responses.
  • Experimental metabolic models.
  • Cellular signalling.
  • Pharmacological pathway interactions.

These investigations provide context for understanding Eloralintide’s proposed research applications.

They do not establish that independently supplied Eloralintide material improves metabolic health in humans.

4. Food-Intake and Satiety-Associated Research

Amylin signalling is relevant to the physiological regulation of food intake.

Research involving amylin-receptor agonists has examined pathways associated with satiety and energy balance.

Relevant scientific topics include:

  • Food-intake-associated signalling.
  • Satiety-related pathways.
  • Central nervous system receptor biology.
  • Metabolic regulation.
  • Experimental behavioural models.
  • Receptor-mediated physiological responses.

Clinical studies involving investigational amylin-receptor agonists have also examined body-weight-related endpoints.

However, trial findings cannot be extrapolated to research materials of unverified identity or composition.

5. Pharmacokinetic and Long-Acting Peptide Research

Eloralintide has been developed as a long-acting investigational compound.

Pharmacokinetic research examines how compounds are distributed, transformed and eliminated within experimental systems.

Relevant research topics include:

  • Peptide stability.
  • Pharmacokinetic profiles.
  • Molecular modifications.
  • Drug exposure.
  • Experimental half-life measurements.
  • Comparative peptide pharmacology.
  • Long-acting ligand design.

These investigations are relevant to understanding the characteristics of investigational peptide therapeutics.

However, the term long-acting does not establish a specific duration of activity for an independently supplied research preparation.

6. Early Clinical Development Research

Eloralintide has been investigated in early clinical development using specifically characterised investigational drug material.

Clinical research may examine:

  • Pharmacokinetic characteristics.
  • Tolerability.
  • Adverse-event profiles.
  • Receptor-associated pharmacology.
  • Body-weight-related endpoints.
  • Metabolic measurements.
  • Dose–response relationships.

Such investigations contribute to the development of scientific knowledge about the investigational compound.

However, early clinical findings do not establish broad therapeutic approval or an accepted safety profile.

They also do not validate the quality or clinical suitability of material supplied by an unrelated manufacturer.

7. Eloralintide Compared With Cagrilintide and Other Amylin Agonists

Eloralintide is sometimes discussed alongside other investigational amylin-receptor agonists.

However, these compounds should not be treated as interchangeable.

Eloralintide (LY3841136):

  • An investigational long-acting amylin-receptor agonist.
  • Reported to show preferential AMY1 receptor activity in laboratory assays.
  • Investigated in receptor pharmacology and early clinical research.
  • Has compound-specific molecular and pharmacological characteristics.

Cagrilintide:

  • A distinct investigational long-acting amylin analogue.
  • Investigated in metabolic and weight-management clinical research.
  • Has a separate molecular structure and development programme.
  • Should not be assumed to have identical receptor selectivity or pharmacokinetics.

Pramlintide:

  • A synthetic amylin analogue with established pharmaceutical use in certain jurisdictions.
  • Has a different molecular structure and regulatory history.
  • Is not chemically equivalent to Eloralintide.

Research findings involving one amylin-receptor agonist should not automatically be attributed to another.

8. Eloralintide Analytical Characterisation and Quality Research

Eloralintide is also relevant to analytical investigations involving peptide identity, molecular structure and material quality.

Laboratories evaluating Eloralintide may investigate:

  • Confirmation of molecular identity.
  • Amino acid sequence verification.
  • Characterisation of molecular modifications.
  • Molecular mass determination.
  • Chromatographic purity profiles.
  • Related peptide impurities.
  • Quantitative content determination.
  • Stability and degradation characteristics.
  • Batch-to-batch analytical consistency.
  • Comparison with verified reference standards.

Analytical techniques may include high-performance liquid chromatography (HPLC), mass spectrometry (MS) and other suitable methods.

A chromatographic purity result alone does not establish that a research material is chemically equivalent to the investigational compound used in published clinical trials.

Eloralintide 10mg Research Peptide Specifications

Peps Aussie lists Eloralintide in a nominal 10mg size.

Specification Details
Product name Eloralintide
Development code LY3841136
Listed size 10mg
Material type Investigational peptide research material
Research classification Amylin-receptor agonist
Reported receptor preference AMY1
Research category Receptor pharmacology and metabolic signalling
Research areas Amylin receptor biology, pharmacokinetics and metabolic endpoints
Exact molecular structure Requires verification against supplier documentation
Supplier Peps Aussie Australia
Intended use Laboratory research and analytical investigation only

The scientific characteristics above describe Eloralintide as discussed in published research. They do not independently verify the identity, composition, purity or content of the supplied material.

Exact molecular identity, amino acid sequence, molecular modifications, salt form, formulation, physical appearance, fill quantity and excipients should be confirmed against the applicable product label and supporting lot documentation.

Important: The name Eloralintide or development code LY3841136 does not independently establish that an unrelated research preparation is identical to the material used in clinical trials.

Eloralintide Certificate of Analysis (COA) and Quality Documentation

Analytical verification is particularly important when evaluating research materials associated with investigational pharmaceutical compounds.

Peps Aussie maintains a dedicated resource where researchers can review available Certificates of Analysis and supporting analytical records.

View Peps Aussie Certificates of Analysis

When evaluating Eloralintide analytical documentation, researchers should consider:

  • Peptide identity: Whether testing supports the declared Eloralintide identity.
  • Sequence verification: Whether the amino acid sequence has been established.
  • Modification characterisation: Whether relevant molecular modifications have been identified.
  • Molecular mass: Whether testing supports the expected molecular characteristics.
  • Purity assessment: Whether suitable methods were used to evaluate impurities.
  • Content determination: Whether quantitative testing supports the declared 10mg quantity.
  • Batch traceability: Whether the certificate corresponds to the supplied production lot.
  • Testing methodology: Whether the analytical techniques are appropriate for the material.
  • Additional testing: Whether relevant contamination or other quality assessments were performed.

High-performance liquid chromatography and mass spectrometry may support peptide characterisation.

However, a general purity result does not independently establish chemical equivalence to pharmaceutical investigational material.

A certificate should be interpreted according to the tests actually performed.

The availability of a certificate does not automatically establish sterility, endotoxin status, a particular purity percentage, pharmaceutical-grade manufacturing or independent verification of every production batch.

Eloralintide Storage and Laboratory Handling

Investigational peptide materials require appropriate handling to support sample integrity and experimental reproducibility.

Storage requirements for Eloralintide depend on the molecular structure, formulation, packaging and validated manufacturer stability information.

Laboratories should consider:

  • Appropriate storage temperature.
  • Protection from light and moisture where necessary.
  • Suitable laboratory containers.
  • Compatibility with analytical solvents.
  • Stability following sample preparation.
  • Potential degradation during storage.
  • Appropriate laboratory handling and disposal procedures.

No universal storage temperature or reconstitution procedure is recommended without verified product-specific documentation.

Storage or preparation information from clinical trial formulations should not automatically be applied to independently supplied research materials.

All laboratory work should be performed by appropriately qualified personnel using validated procedures and suitable safety controls.

Eloralintide 10mg Australia – Product Availability and Shipping

Peps Aussie maintains an Australian-based catalogue of research peptides and laboratory materials for scientific and analytical applications.

Eloralintide 10mg is the currently listed nominal product size.

Pricing and ordering availability should be confirmed through the product selection area. Inventory is currently pending confirmation.

For current information regarding Australian dispatch, delivery arrangements, processing times and applicable restrictions, visit the Peps Aussie Shipping Policy.

Frequently Asked Questions About Eloralintide

What is Eloralintide?

Eloralintide, also known as LY3841136, is an investigational long-acting amylin-receptor agonist with reported preferential activity at the AMY1 receptor.

What is Eloralintide studied for?

Published receptor studies and early clinical trials have examined Eloralintide’s pharmacology, tolerability, pharmacokinetic characteristics and metabolic endpoints.

Is Eloralintide the same as LY3841136?

Yes. LY3841136 is the development code associated with Eloralintide.

What is the AMY1 receptor?

AMY1 is an amylin receptor complex formed through interactions between the calcitonin receptor and receptor activity-modifying protein 1 (RAMP1).

Is Eloralintide a GLP-1 receptor agonist?

Eloralintide is primarily described as an investigational amylin-receptor agonist. It should not be classified as a GLP-1 receptor agonist without direct supporting pharmacological evidence.

Is Eloralintide the same as cagrilintide?

No. Eloralintide and cagrilintide are distinct investigational amylin-receptor agonists with different molecular structures and development programmes.

Does Eloralintide cause weight loss?

Clinical research has investigated body-weight-related endpoints using specifically characterised investigational Eloralintide material. These findings do not establish clinical suitability or efficacy for an independently supplied research vial.

Has Eloralintide been studied in humans?

Yes. Eloralintide has entered clinical investigation. However, clinical trial findings apply to the specific investigational drug material studied and do not validate unrelated research preparations.

Is Eloralintide approved for weight management?

Eloralintide remains investigational in the context described here. No therapeutic approval is claimed for the Peps Aussie research product.

What size does Peps Aussie list?

Peps Aussie lists Eloralintide in a 10mg nominal size. Researchers should verify the individual vial label and supporting analytical documentation.

Does Eloralintide have a Certificate of Analysis?

Available analytical documentation can be reviewed through the Peps Aussie Certificates of Analysis page. Researchers should confirm that any applicable certificate corresponds to the specific production lot and evaluate the tests performed.

How should Eloralintide be stored?

Storage requirements depend on the molecular structure, formulation and validated stability characteristics. Follow the manufacturer’s product-specific documentation and established laboratory procedures.

Is Eloralintide approved for human or veterinary use?

No medical or veterinary approval is claimed for the Peps Aussie Eloralintide research product.

This product is not supplied for human or animal consumption, administration, diagnosis, prevention or treatment.

Eloralintide Research Peptides at Peps Aussie Australia

Peps Aussie maintains a catalogue of laboratory research peptides and scientific materials for researchers investigating molecular biology, receptor pharmacology and metabolic signalling.

Eloralintide remains a subject of scientific interest because of its reported AMY1 receptor preference and its investigation in receptor pharmacology and early clinical development.

Researchers evaluating Eloralintide 10mg should prioritise accurate molecular identification, appropriate analytical documentation, batch traceability and validated laboratory procedures.

Explore the Peps Aussie research catalogue at pepsaussie.com.


Research Use Only Disclaimer

Eloralintide 10mg is intended strictly for laboratory research and analytical purposes only.

This product is not intended for human or animal consumption, injection, administration, weight management, therapeutic use or clinical treatment.

Descriptions of published scientific research are provided for educational and informational purposes only. They do not establish weight-loss benefits, metabolic improvement, clinical safety or therapeutic suitability for the material offered.

Clinical trial findings involving specifically manufactured investigational Eloralintide do not establish the identity, quality or clinical suitability of independently supplied research material.

No dosing, self-administration or therapeutic guidance is provided.

Additional information

Size

10mg

Reviews

There are no reviews yet.

Reviews here are by invitation. We email a link once your order has arrived, so every review comes from someone who received the product. Lost the email? Find your review link.

Related Products

Search Products